Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
2019-004818-34Phase 3Active
- Sponsor
- Cancer Trials Ireland
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide + ADT + radiation with Placebo + ADT + radiation (2 arms). Primary endpoint: Metastasis-free survival. Started May 2020; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2019-004818-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004818-34.